FDA staff raises safety concerns over Lilly/Incyte arthritis drug
(Reuters) - U.S. Food and Drug Administration staff flagged concerns on Thursday about potentially fatal blood clots from higher doses of a rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp, a fresh setback after regulators declined to approve the treatment last year.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Arthritis | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology